Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
BMC Cancer
|
September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Critical Reviews in Oncology/Hematology
|
January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Oncology
|
September 20, 2007
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Gynecologic Oncology
|
October 9, 2016
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)
Claudia Marchetti, Gabriella Ferrandina, Gennaro Cormio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, et al.
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
BMC Cancer
|
September 3, 2008
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Critical Reviews in Oncology/Hematology
|
January 31, 2009
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Oncology
|
September 20, 2007
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study
Sandro Pignata, Gabriella Ferrandina, Giovanna Scarfone, et al.
Gynecologic Oncology
|
October 9, 2016
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)
Claudia Marchetti, Gabriella Ferrandina, Gennaro Cormio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, et al.
Gynecologic Oncology
|
December 21, 2016
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, et al.
The Lancet. Oncology
|
July 13, 2016
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
Marina Bagnoli, Silvana Canevari, Daniela Califano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2017
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Sandro Pignata, Giovanni Scambia, Alessandra Bologna, et al.
Gynecologic Oncology
|
April 29, 2019
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
Gennaro Daniele, Laura Arenare, Giovanni Scambia, et al.
Oncotarget
|
September 23, 2016
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Francesco Perrone, Gustavo Baldassarre, Stefano Indraccolo, et al.
Page
of 3